PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

Immunotherapy, in the form of hematopoietic stem cell transplantation (HSCT), has been part of the standard of care in the treatment of acute leukemia for over 40 years. Trials evaluating novel immunotherapeutic approaches, such as targeting the programmed death-1 (PD-1) pathway, have unfortunately...

Full description

Bibliographic Details
Main Authors: Patrick Williams, Mien-Chie Hung, Jennifer L Hsu, Marina Konopleva, Michael A Curran, Zhou Jiang, Natalia Baran, Xuelin Huang, Renee L Chin, Paul Koller, Karine Harutyunyan, Antonio Cavazos, Saradhi Mallampati, Xian Sun, Heng-Huan Lee
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/10/e006619.full

Internet

https://jitc.bmj.com/content/11/10/e006619.full

Similar Items